Rationale Macrolides are reported to reduce exacerbation of COPD and also Zymography: MMP9 enzyme activity was measured by gelatin zymography. 5 μl of supernatants were diluted with 5 μl Laemli sample buffer (Bio-Rad) and were loaded on a Novex ® 10 % Zymogram (Gelatin) gel (Invitrogen). After electrophoresis (90 min, 125 V, 35 mA, 5 W) gels were incubated with 1× Novex® zymogram renaturing buffer (Invitrogen) for
41.6 ± 1.9 μM n/a n/a IC50 n/a 374.1 μM show anti-inflammatory effects in vitro. However the anti-inflammatory efficacies of current macrolides are not optimum. Here we found that CEM-101, a novel macrolide/fluoroketolide (starting Phase 2) which has activities against wide range of bacteria causing pneumonia, showed more potent anti-inflammatory effects than any other macrolides being marketed. Methods: Effects of CEM-101 on PMA-induced MMP9 production and LPS-induced IL-8 and TNFα release in U937 monocytic cells have been evaluated and compared with the effects of erythromycin (EM), clarithromycin (CAM), azithromycin (AZM) and mA, 5 W) gels were incubated with 1 Novex® zymogram renaturing buffer (Invitrogen) for 30 min at room temperature with gentle agitation. Gels were then rinsed in 1× Novex® zymogram developing buffer (Invitrogen) for 30 min at room temperature with gentle agitation prior to overnight incubation in the developing buffer at 37°C. After incubation the gels were stained using the colloidal blue staining kit (Invitrogen) with buffer containing 20 % methanol and 70 % distilled water to visualize the zymogen bands. Relevant band intensities were quantified by densitometric analysis using the UVP GelDoc-It system. . Results: CEM-101 concentration-dependently inhibited MMP9/IL-8/TNFα production in U937 with IC 50 s of 28.9 ± 1.6 μM, 78.2 ± 9.5 μM and 41.6 ± 1.9 μM respectively. In contrast, CAM had 10 times less antiinflammatory effects than CEM-101. EM, AZM and TEL did not show significant anti-inflammatory effects. Conclusion: CEM-101 shows better anti-inflammatory profiles compared with macrolides currently used in clinic, and will be a promising anti-inflammatory and anti bacterial macrolide/fluoroketolide for the treatment of COPD
Summary/ Conclusion
PMA differentiated U937 cells were pre treated with macrolide compounds (CEM 101 and Telithromycin (TEL); 10 to 100 μM, Erythromycin (EM), Clarithromycin (CAM), and Azithromycin (AZM); 33 to 333 μM) for 1 hr, followed by LPS (100 ng/ml) stimulation for 4 hrs. LPS-induced TNFα release was evaluated by ELISA. IC 50 s for each macrolide on LPS-induced TNFα production were calculated using Prism. Values represent means of three experiments ± SEM. # p < 0.05, ## p < 0.01 (vs. non-treatment control), * p < 0.05, ** p < 0.01 (vs. positive control treated with LPS only). n/a; not applicable.
Aim
To explore whether a novel macrolide/fluoroketolide, CEM-101, has more potent anti-inflammatory effects than other macrolides currently used clinically. • CEM-101 remarkably reduced PMA-induced MMP9 production in U937 cells. The IC 50 value for CEM-101 on MMP9 production (11.7 ± 2.8 μM) was 10 times superior compared to IC 50 s for clarithromycin, azithromycin and telithromycin. On the other hand, erythromycin did not decrease MMP9 production even at higher concentration.
• CEM-101 dose-dependently inhibited LPS-induced IL-8 and TNFα production with IC 50 s of 78.2 ± 9.5 μM, 41.6 ± 1.9 μM respectively. In contrast, the inhibitory effect of clarithromycin was 10 times less than CEM 101 Erythromycin azithromycin and 
Introduction
• Chronic obstructive pulmonary disease (COPD) is characterized by chronic airway inflammation and is caused by a mixture of small airway obstruction and emphysema. As one of the molecular mechanisms of airway inflammation in COPD, there is increased expression of specific inflammatory genes, such as IL-8, TNFα, and matrix metalloproteinase 9 (MMP9) [1 2] clarithromycin was 10 times less than CEM-101. Erythromycin, azithromycin and telithromycin inhibited neither LPS-induced IL-8 nor TNFα.
• Our findings shows that a novel macrolide, CEM-101 exerted superior antiinflammatory effects than any other macrolides available clinically, which might be due to enhancement of HDAC activity/expression by CEM-101 (ATS 2010, Poster #3527). CEM-101 will be a promising anti-inflammatory drug and a viable option for the treatment of COPD.
U937 cells pre-treated with macrolide compounds (CEM-101 and Telithromycin (TEL); 10 to 100 μM, Erythromycin (EM), Clarithromycin (CAM), and Azithromycin (AZM); 33 to 333 μM) for 1 hr, followed by PMA (50 ng/ml) treatment for 48 hrs. After 48 hrs supernatants were collected for zymography. MMP9 enzyme activity was measured by gelatin zymography. Data are expressed as fold changes against positive control treated with PMA only. IC 50 s for each macrolide on PMA-induced MMP9 were calculated using Prism. Values represent means of three experiments ± SEM. ## p < 0.01 (vs. non-treatment control), * p < 0.05, ** p < 0.01 (vs. positive control treated with PMA only). n/a; not applicable.
Results 2: Effects of macrolides on LPS-induced IL-8 production
• Clarithromycin has been reported to reduce IL-8 and TNFα productions in sputum from COPD patients [3] . Further, erythromycin and clarithromycin therapy reduced exacerbation of COPD [4, 5] . These findings indicate that macrolides have antiinflammatory properties independently of their anti-bacterial effects and might exert an anti-inflammatory effect in COPD as well as other inflammatory airway disease (e.g. diffuse panbronchiolitis, bronchiectasis).
• A novel macrolide/fluoroketolide, CEM-101 which was developed by Cempra Pharmaceutical Inc has PMA-differentiated U937 cells were pre-treated with macrolide compounds (CEM-101 and Telithromycin (TEL); 10 to 100 μM, Erythromycin (EM), Clarithromycin (CAM), and Azithromycin (AZM); 33 to 333 μM) for 1 hr, followed by LPS (100 ng/ml) stimulation for 4 hrs. LPS-induced IL-8 release was evaluated by ELISA. IC 50 s for each macrolide on LPS-induced IL-8 production were calculated using Prism. Values represent means of three experiments ± SEM. ## p < 0.01 (vs. non-treatment control), ** p < 0.01 (vs. positive control treated with LPS only). n/a; not applicable.
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